Core–shell particles made of calcium carbonate and coated with biocompatible polymers using the Layer-by-Layer technique can be considered as a unique drug-delivery platform that enables us to load different therapeutic compounds, exhibits a high biocompatibility, and can integrate several stimuli-responsive mechanisms for drug release. However, before implementation for diagnostic or therapeutic purposes, such core–shell particles require a comprehensive in vivo evaluation in terms of physicochemical and pharmacokinetic properties. Positron emission tomography (PET) is an advanced imaging technique for the evaluation of in vivo biodistribution of drug carriers; nevertheless, an incorporation of positron emitters in these carriers is needed. Here, for the first time, we demonstrate the radiolabeling approaches of calcium carbonate core–shell particles with different sizes (CaCO3 micron-sized core–shell particles (MicCSPs) and CaCO3 submicron-sized core–shell particles (SubCSPs)) to precisely determine their in vivo biodistribution after intravenous administration in rats. For this, several methods of radiolabeling have been developed, where the positron emitter (68Ga) was incorporated into the particle’s core (co-precipitation approach) or onto the surface of the shell (either layer coating or adsorption approaches). According to the obtained data, radiochemical bounding and stability of 68Ga strongly depend on the used radiolabeling approach, and the co-precipitation method has shown the best radiochemical stability in human serum (96–98.5% for both types of core–shell particles). Finally, we demonstrate the size-dependent effect of core–shell particles’ distribution on the specific organ uptake, using a combination of imaging techniques, PET, and computerized tomography (CT), as well as radiometry of separate organs. Thus, our findings open up new perspectives of CaCO3-radiolabeled core–shell particles for their further implementation into clinical practice.

No abstract

No abstract

No abstract

No abstract

No abstract

Nowadays chemistry of 68Ga‐labelled radiopharmaceuticals is one of the drivers for Positron Emission Tomography (PET). Buffers solutions for radiolabelling play one of the important roles here. Despite HEPES buffer providing high radiochemical conversions, its use is undesirable due to high toxicity. In this article we report a simple procedure involving usage of aqueous triethanolammonium (TEA) and tris(hydroxymethyl)methyl‐ammonium (TRIS) salts of biologically active carboxylic acids in a process of gallium‐68 complexation with PSMA‐HBED‐CC. These salts provide not only high radiochemical conversions but also are already widely used in biochemistry, molecular biology, agriculture and medicine as drugs of a wide spectrum of action and growth stimulating drugs (Trekrezan™, Chlorokrezacin™).

No abstract